Cellular 'power plants' control inflammation

"We found that mitochondria provide a kind of decision-making aid: they regulate whether a cell undergoes clean, silent apoptosis or releases pro-inflammatory messenger substances," explains Prof. Dr Olaf Groß, head of the study, a scientist at the Institute of Neuropathology at the Medical Center -- University of Freiburg and a member of the Cluster of Excellence CIBSS -- Centre for Integrative Biological Signalling Studies at the University of Freiburg. "This finding helps us to better understand how the body maintains a balance between cell protection and defence mechanisms. This could open up new avenues for the treatment of inflammatory diseases." The research work was funded as part of several collaborative research centres at the University of Freiburg.

A complex interplay for good health

The universal "fuel source" for cellular activity is ATP (adenosine triphosphate). If the ATP in the mitochondria drops sharply, a protein important for apoptosis, known as cytochrome c, remains trapped in the mitochondria and the cell does not die, even if it receives the signal to do so from outside. Instead, the mitochondria activate mechanisms that trigger an inflammatory response, which puts the tissue on alert and prepares it for a possible threat.

The researchers have now discovered that a special "sensor" in the cells, known as NLRP3, is activated when the mitochondria cease energy production. However, a second signal from other areas of the cell is needed to activate the NLRP3 sensor. This so-called "two-signal mechanism" ensures that inflammation is only triggered in the event of serious danger, thus protecting healthy cells. This enables the body to react to threats in a targeted manner while at the same time preventing unnecessary inflammation that could damage the tissue.

New options for treating inflammatory diseases

This discovery could be helpful for the treatment of diseases in which inflammatory processes play a role -- such as gout, type 2 diabetes or severe cases of COVID-19. "In the future, drugs could be specifically designed to mitochondria or the activation of NLRP3 in order to better control inflammation and, on the one hand, to prevent damage to healthy tissue and, on the other, to promote the immune response to infection or the rejection of cancer by the immune system," says Groß.